Advertisement

Immunotherapy of Microbial Diseases

  • K. Noel Masihi

Abstract

Marvels of modem medicine have apparently tamed a multitude of microbial infections. Vaccination has had a major impact in the control of important diseases including smallpox, yellow fever, polio, measles, mumps, rubella, diphtheria, tetanus, and pertusis. It is, nonetheless, enlightening to note that immunotherapeutic intervention in the form of immunization predates the postulates of infection or immunology. Edward Jenner discovered the smallpox vaccination in 1780. Since then only around 25 vaccines against various infectious diseases have been licensed and general widespread use has been restricted to about 10 vaccines. It is disconcerting that there are a vast number of diseases afflicting humans and domestic mammals for which no vaccines or specific chemotherapy will be available in the near future. In addition, infections that caused ravages in the 19th century, such as tuberculosis, are resurging with vehemence. Recent episodes of plague, diphtheria, cholera, and Ebola virus, diseases long thought to be under control, have heightened public awareness of infectious diseases.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Replication Rift Valley Fever Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abath, F. G., Coutinho, E. M., Montenegro, S. M., Gomes, Y. M., and Carvalho, A. B., 1988, The use of non-specific immunopotentiators in experimental Trypanosoma cruzi infection, Trans. R. Soc. Trop. Med. Hyg.82: 73–76.PubMedGoogle Scholar
  2. Akridge, R. E., Oyafuso, L. K. M., and Reed, S. G., 1994, IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages, J. Immunol.153: 5782–5789.PubMedGoogle Scholar
  3. Aldovini, A., and Young, R. A., 1991, Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines, Nature 351: 479–482.PubMedGoogle Scholar
  4. Alexander, H. R., Doherty, G. M., Buresh, C. M., Venzon, D. J., and Norton, J. A., 1991, A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice, J. Exp. Med.173: 1029–1032.PubMedGoogle Scholar
  5. Ankel, H., Mittnacht, S., and Jacobsen, H., 1985, Antiviral activity of prostaglandin A on encephalomyocarditis virus-infected cells: A unique effect unrelated to interferon, J. Gen. Virol.66: 2355–2364.PubMedGoogle Scholar
  6. Ankel, H., Turriziani, O., and Antonelli, G., 1991, Prostaglandin A inhibits replication of human immunodeficiency virus during acute infection, J. Gen. Virol.72: 2797–2800.PubMedGoogle Scholar
  7. Aoyagi, K., Abe, F., Nemoto, K., Abe, S., Ishizuka, M., Takeuchi, T., and Yamaguchi, H., 1994, The novel immunostimulant N-563, an analogue of deoxyspergualin, promotes resistance to Candida albicans infection in mice, J. Antibiot.47: 1077–1083.PubMedGoogle Scholar
  8. Appelberg, R., Castro, A. G., Pedrose, J., Silva, R. A., Orme, I. M., and Minóprio, P., 1994, Role of gamma interferon and tumor necrosis factor alpha during T-cell-independeńt and -dependent phases of Mycobacterium avium infection, Infect. Immun.62: 3962–3971.PubMedGoogle Scholar
  9. Arakawa, T., Hsu, Y.-R., Toth, E, and Stebbing, N., 1987, The antiviral activity of recombinant human tumor necrosis factor, J. Interferon Res.7: 103–105.PubMedGoogle Scholar
  10. Asano, T., McWaters, A., An, T., Matsushima, K., and Kleinerman, E. S., 1994, Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes, J. Pharmacol. Exp. Ther.268: 1032–1039.PubMedGoogle Scholar
  11. Aukrust, P., Liabakk, N. M., Mueller, F., Lien, E., Espevik, T., and Froland, S.S., 1994, Serum levels of tumor necrosis factor-alpha TNF-alpha and soluble TNF receptors in human immunodeficiency virus type 1 infection-Correlations to clinical, immunologic, and virologic parameters, J. Infect. Dis.169: 420–424.PubMedGoogle Scholar
  12. Azuma, I., Yoo, Y. C., Tamura, M., Yoshida, R., Yoshimatsu, K., Arikawa, J., and Yamanishi, K., 1994, Protective activity of MDP-Lys(L18) on hantavitus infection in newborn mice and potentiation of antigenicity by B30-MDP and MDP-Lys(L18) of inactivated hantavirus strain B-1 vaccine and recombinant hepatitis B virus surface antigen, in: Immunotherapy of Infections (K. N. Masihi, ed.), Dekker, New York, pp. 191–203.Google Scholar
  13. Babineau, T. J., Marcello, P., Swails, W., Kenler, A., Bistrian, B., and Forse, R. A., 1994, Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients, Ann. Surg.220: 601–609.PubMedGoogle Scholar
  14. Bader, T., and Ankel, H., 1990, Inhibition of primary transcription of vesicular stomatitis virus by prostaglandin Al, J. Gen. Virol.71: 2823–2832.PubMedGoogle Scholar
  15. Bahr, G., Darcissac, E., Bevec, D., Dukor, P., and Chedid, L., 1995, Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide, Int. J. Immunopharmacol.17: 117–131.PubMedGoogle Scholar
  16. Barral-Neto, M., Barral, A., Brownell, C. E., Skeiky, Y. A. W., Ellingwoth, L. R., Twardzik, D. R., and Reed, S. G., 1992, Transforming growth factor-beta in leishmanial infection: A parasite escape mechanism, Science 257: 545–548.Google Scholar
  17. Bauer, J., and Hermann, E, 1991, Interleukin-6 in clinical medicine, Ann. Hematol.62: 203–210.PubMedGoogle Scholar
  18. Bazzoni, F., Cassatella, M. A., Rossi, F., Ceska, M., Dewald, B., and Baggiolini, M., 1991, Phagocytosing neutrophils produce and release high amounts of neutrophil-activating peptide 1/interleukin 8, J. Exp. Med.173: 771–774.PubMedGoogle Scholar
  19. Beck, J. M., Liggitt, H. D., Brunette, E. N., Fuchs, H. J., Shellito, J. E., and Debs, R. J., 1991, Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon, Infect. Immun.59: 3859–3862.PubMedGoogle Scholar
  20. Belosevic, M., Finbloom, D. S., Meltzer, M., and Nacy, C. A., 1990, IL-2. A cofactor for induction of activated macrophage resistance to infection, J. Immunol.145: 831–839.PubMedGoogle Scholar
  21. Benavente, J., Esteban, M., Jaffe, B. M., and Santoro, M. G., 1984, Selective inhibition of viral gene expression as the mechanism of the antiviral action of PGA1 in vaccinia virus-infected cells, J. Gen. Virol.65: 599–608.PubMedGoogle Scholar
  22. Bender, A., Amann, U., Jäger, R., Nain, M., and Gemsa, D., 1993, Effect of granulocyte/macrophage colony-stimulating factor on human monocytes infected with influenza A virus, J. Immunol.151: 5416–5424.PubMedGoogle Scholar
  23. Bergamini, A., Perno, C. F., Dini, L., Capozzi, M., Pesce, C. D., Ventura, L., Cappannoli, L., Falasca, L., Milanese, G., Caliò, R., and Rocchi, G., 1994, Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding, Blood 84: 3405–3412.PubMedGoogle Scholar
  24. Bermudez, L. E., and Young, L. S., 1991, Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages, J. Immunol.146: 265–270.PubMedGoogle Scholar
  25. Bermudez, L. E. M., Stevens, P., Kolonoski, P., Wu, M., and Young, L. S., 1989, Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor, J. Immunol.143: 2996–3000.PubMedGoogle Scholar
  26. Bermudez, L. E., Covaro, G., and Remington, J., 1993, Infection of murine macrophages with Toxoplasma gondii is associated with release of transforming growth factor beta and downregulation of expression of tumor necrosis factor receptors, Infect. Immun.61: 4126–4130.PubMedGoogle Scholar
  27. Bernstein, D. I., and Harrison, C. J., 1989, Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections, Antimicrob. Agents Chemother.33: 1511–1515.PubMedGoogle Scholar
  28. Bessler, W. G., Kleine, B., Biesert, L., Schlecht, S., Schaude, R., Wiesmüller, K.-H., Metzger, J., and Jung, G., 1990, Bacterial surface components as immunomodulators, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 37–48.Google Scholar
  29. Bessler, W., Beck, W., Wiesmüller, K. H., and Jung, G., 1994, Modulation of the immune system by bacterial products: Hapten-specific humoral immune responses induced by lipopeptides conjugated to T helper cell epitopes, in: Immunotherapy of Infections (K. N. Masihi, ed.), Dekker, New York, pp. 329–338.Google Scholar
  30. Bhalla, K., Birkhofer, M., Grant, S., and Graham, G., 1989, The effect of recombinant human granulocytemacrophage colony-stimulating factor on AZT-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells, Exp. Hematol.17: 17–20.PubMedGoogle Scholar
  31. Black, C. M., Israelski, D. M., Suzuki, Y., and Remington, J. S., 1989, Effect of recombinant tumor necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi, Immunology 68: 570–574.PubMedGoogle Scholar
  32. Blanchard, D. K., Djeu, J. Y., Klein, T. W., Friedman, H., and Stewart, W. E., 1988, Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function, J. Leukocyte Biol.43: 429–435.PubMedGoogle Scholar
  33. Bogdan, C., Vodovotz, Y., and Nathan, C., 1991, Macrophage deactivation by interleukin 10, J. Exp. Med.174: 1549–1555.PubMedGoogle Scholar
  34. Botros, S. S., Hassan, S. I., El-Nahal, H. M., Azab, M. E., Shaker, Z. A., and El-Garem, A., 1989, Levamisole restored the compromised state of immunity after specific chemotherapy in experimental Schistosomiasis mansoni, Immunopharmacol. Immunotoxicol.11: 611–629.PubMedGoogle Scholar
  35. Buchmeier, N. A., and Schreiber, R. D., 1985, Requirement of endogenous interferon-gamma for resolution of Listeria monocytogenes infection, Immunology 82: 7404–7408.Google Scholar
  36. Bui, T., Dykers, T., Hu, S. L., Faltynek, C. R., and Ho, R. K., 1994, Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein, J. AIDS 7: 799–806.Google Scholar
  37. Bukowski, J. F., Yang, H., and Welsh, R. M., 1988, The antiviral effect of lymphokine-activated killer cells: characterization of the effector cells mediating prophylaxis, J. Virol.62: 3642–3648.PubMedGoogle Scholar
  38. Burke, R. L., Goldbeck, C., Ng, P., Stanberry, L., Ott, G., and Van Nest, G., 1994, The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine, J. Infect. Dis.170: 1110–1119.PubMedGoogle Scholar
  39. Byars, N. E., Fraser-Smith, E. B., Pecyk, R. A., Welch, M., Nakano, G., Burke, R. L., Hayward, A. R., and Allison, A. C., 1994, Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection Vaccine 12: 200–209.PubMedGoogle Scholar
  40. Campos, R., Pinto, P. L., Amato, N. V., Matsubara, L., Miyamoto, A., de Carvalho, S. A., Takiguti, C. K., and Moreira, A. A., 1989, Treatment of experimental infection by Strongyloides venezuelensis in rats, with the use of injectable ivermectin and levamisole, Rev. Inst. Med. Trop. Sao Paulo 31: 48–52.PubMedGoogle Scholar
  41. Casey, L. C., Balk, R. A. and Bone, R. C., 1993, Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome, Ann. Intern. Med.119: 771–778.PubMedGoogle Scholar
  42. Chan, W. L., Ziltener, H. J., and Liew, F. W., 1990, Interleukin-3 protects mice from acute herpes simplex virus infection, Immunology 71: 358–363.PubMedGoogle Scholar
  43. Chang, H. R., Grau, G. E., and Pechere, J. C., 1990, Role of TNF and IL-1 in infections with Toxoplasma gondii, Immunology 69: 33–37.PubMedGoogle Scholar
  44. Chao, C. C., Hu, S., Gekker, G., Novick, W. J., Remington, J. S., and Peterson, P. K., 1993, Effects of cytokines on multiplication of Toxoplasma gondii in microglial cells, J. Immunol.150: 3403–3410.Google Scholar
  45. Cheadle, W. G., Hanasawa, K., Gallinaro, R. N., Nimmanwudipong, T., Kodama, M., and Polk, H. C., 1991, Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis, Surgery 110: 785–791.PubMedGoogle Scholar
  46. Cheers, C., Hill, M., Haigh, A. M., and Stanley, E. R., 1989, Stimulation of macrophage phagocytic but not bactericidal activity by colony-stimulating factor 1, Infect. Immun.57: 1512–1516.PubMedGoogle Scholar
  47. Chihara, G., 1990, Lentinan and its related polysaccharides as host defence potentiators: Their application to infectious diseases and cancer, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 9–18.Google Scholar
  48. Chong, K.-T., 1987, Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria, Infect. Immun.55: 668–673.PubMedGoogle Scholar
  49. Choromanski, L., and Kuhn, R., 1985, Interleukin-2 enhances specific and nonspecific immune responses in experimental Chagas disease, Infect. Immun.50: 354–357.PubMedGoogle Scholar
  50. Clark, I. A., Hunt, N. H., Butcher, G. A., and Cowden, W. B., 1987, Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon-gamma or tumor necrosis factor, and its enhancement by butylated hydroxyanisole, J. Immunol.139: 3493–3496.PubMedGoogle Scholar
  51. Cohen, A. M., Hines, D. K., Korach, E. S., and Ratzkin, B. J., 1988, In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor, Infect. Immun.56: 2861–2865.PubMedGoogle Scholar
  52. Curfs, J. H., Van der Meer, J. W., Sauerwein, R. W., and Eling, W. M., 1990, Low dosages of interleukin 1 protect mice against lethal cerebral malaria, J. Exp. Med.172: 1287–1291.PubMedGoogle Scholar
  53. Czuprynski, C. J., and Brown, J. F., 1987, Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance, Infect. Immun.55: 2061–2065.PubMedGoogle Scholar
  54. Daniels, H. M., Meager, A., Eddleston, A. L., Alexander, G. J., and Williams, R., 1990, Spontaneous production of tumor necrosis factor alpha and interleukin-1 beta during interferon alpha treatment of chronic HBV infection, Lancet 335: 875–877.PubMedGoogle Scholar
  55. Delfino, D., Chiofalo, M. S., Altavilla, D., Arena, A., Iannello, D., and Mastroeni, R, 1990, Interaction of rat macrophages with Leishmania infantum: role of tumor necrosis factor, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 271–277.Google Scholar
  56. Denis, M., 1991a, Growth of Listeria monocytogenes in murine macrophages and its modulation by cytokines, activation of bactericidal activity by interleukin-4 and interleukin-6, Can. J. Microbiol.37: 253–257.PubMedGoogle Scholar
  57. Denis, M., 1991b, Modulation of Mycobacterium lepraemurium growth in murine macrophages: Beneficial effect of tumor necrosis factor and granulocyte-macrophage colony-stimulating factor, Infect. Immun.59: 705–707.PubMedGoogle Scholar
  58. Denis, M., and Gregg, E. O., 1991, Modulation of Mycobacterium avium growth in murine macrophages: Reversal of unresponsiveness to interferon-gamma by indomethacin or interleukin-4, J. Leukocyte Biol.49: 65–72.PubMedGoogle Scholar
  59. Denis, M., Campbell, D., and Gregg, E. O., 1991, Interleukin-2 and granulocyte-macrophage colony-stimulating factor stimulate growth of a virulent strain of Escherichia coli, Infect. Immun.59: 1853–1856.PubMedGoogle Scholar
  60. Déprez, B., Gras-Masse, H., Martinon, F., Gomard, E., Lévy, J.-R, and Tartar, A., 1995, Pimelautide or trimexautide as built-in adjuvants associated with an HIV-l-derived peptide: Synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated response, J. Med. Chem.38: 459–465.PubMedGoogle Scholar
  61. De Simone, C., Famularo, G., Tzantzoglou, S., Moretti, S., and Jirillo, E., 1991, Inosine pranobex in the treatment of HIV infection: A review, Int. J. Immunopharmacol.13(Suppl. 1): 19–27.PubMedGoogle Scholar
  62. Dezube, B. J., 1994, Pentoxifylline for the treatment of infection with human immunodeficiency virus, Clin. Infect. Dis.18: 285–287.PubMedGoogle Scholar
  63. Dianzani, C., Colangelo, D., Tonso, E., Guidotto, S., and Viano, I., 1994, In vivo antiviral effects of pidotimod, Arzneim. Forsch.44: 1431–1433.Google Scholar
  64. Doherty, P., Allan, J. E., and Clark, I. A., 1989, Tumor necrosis factor inhibits the development of viral meningitis or induces rapid death depending on the severity of inflammation at the time of administration, J. Immunol 142: 3576–3580.PubMedGoogle Scholar
  65. Domke-Opitz, I., and Kirchner, H., 1990, Stimulation of macrophage by endotoxin results in the reactivation of a persistent herpes simplex virus infection, Scand. J. Immunol.32: 69–75.PubMedGoogle Scholar
  66. Eizuru, Y., Nakagawa, N., Hamasuna, R., and Minamishima, Y., 1992, Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection, Nat. Immun.11: 225–236.PubMedGoogle Scholar
  67. Esparza, I., Gonzalez, J. C., and Vinuela, E., 1988, Effect of interferon-alpha, interferon-gamma and tumour necrosis factor on African swine fever virus replication in porcine monocytes and macrophages, J. Gen. Virol.69: 2973–2980.PubMedGoogle Scholar
  68. Feduchi, E., and Carrasco, L., 1991, Mechanism of inhibition of HSV-1 replication by tumor necrosis factor and interferon gamma, Virology 180: 822–825.PubMedGoogle Scholar
  69. Feduchi, E., Alonso, M. A., and Carrasco, L., 1989, Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus, J. Virol.63: 1354–1359.PubMedGoogle Scholar
  70. Folks, T. M., Clouse, K. A., Justement, J., Rabson, A., Duh, E., Kehrl, J. H., and Fauci, A. S., 1989, Tumor necrosis factor-alpha induces the expression of T-cell clone, Proc. Natl. Acad. Sci. USA 86: 2365–2368.PubMedGoogle Scholar
  71. Franek, J., and Malina, J., 1990, Immunomodulatory capacity of drugs evaluated in a mouse model of Klebsiella pneumoniae infection, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 55–58.Google Scholar
  72. Galassi, D., Galassi, P., Pelliccioni, A., and Semprini, P., 1986, Clinical results obtained in cattle and swine by means of biological immunostimulators, Comp. Immun. Microbiol. Infect. Dis.9: 285–295.Google Scholar
  73. Gallin, J. I., 1991, Interferon-gamma in the management of chronic granulomatous disease, Rev. Infect. Dis.13: 973–978.PubMedGoogle Scholar
  74. Gazzinelli, R. T., Hieny, S., Wynn, T. A., Wolf, S., and Sher, A. 1993, Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts, Proc. Natl. Acad. Sci. USA 90: 6115–6119.PubMedGoogle Scholar
  75. Gendelman, H. E., Orenstein, J. M., Martin, M. A., Ferrua, C., Mitra, R., Phipps, T., Wahl, L. A., Lane, H. C., and Fauci, A. S., 1988, Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes, J. Exp. Med.167: 1428–1441.PubMedGoogle Scholar
  76. Ghadirian, E., 1990, In vitro effect of human recombinant tumor necrosis factor on Entamoeba histolytica trophozoites, Immunobiology 180: 339–350.PubMedGoogle Scholar
  77. Gidoh, M., and Tsutsumi, S., 1989, The inhibitory effects by combined doses of DDS and several immunostimulants on the growth of leprosy bacilli inoculated into footpads of hybrid nude mice, Nippon Rai. Gakkai. Zasshi 58: 241–249.PubMedGoogle Scholar
  78. Gladue, R. P., Laquerre, A. M., Magna, H. A., Carrol, L. A., O’Donnell, M., Changelian, P. S., and Franke, A. E., 1994, In vivo augmentation of IFN-gamma with a rIL-12 human/mouse chimera: Pleiotropic effects against infectious agents in mice and rats, Cytokine 6: 318–328.PubMedGoogle Scholar
  79. Goronzy, J., Weyand, C., Quan, J., Fathman, C. G., and O’Hanley, P., 1989, Enhanced cell-mediated protection against fatal Escherichia coli septicemia induced by treatment with recombinant IL-2, J. Immunol.142: 1134–1138.PubMedGoogle Scholar
  80. Gottlieb, A. A., and Gottlieb, M. S., 1990, Experience with IMREG-1, a leukocyte derived immunomodulator on candidiasis and progression of disease in patients with AIDS-related complex, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 121–128.Google Scholar
  81. Grau, G. E., Kindler, J., Piguet, P. F., Lambert, P. H., and Vassali, P., 1988, Prevention of experimental cerebral malaria by anticytokine antibodies: IL-3 and granulocyte-macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation, J. Exp. Med.168: 1499–1504.PubMedGoogle Scholar
  82. Greil, J., Bodendorfer, B., Rollinghoff, M., and Solbach, R., 1988, Application of recombinant granulocytemacrophage colony-stimulating factor has a detrimental effect in experimental murine leishmaniasis, Eur. J. Immunol.18: 1527–1533.PubMedGoogle Scholar
  83. Gruszecki, W., Masihi, K. N., Labischinski, H., and Bradaczek, H., 1988, Synthesis and some biological activities of a novel glucofuranose immunomodulator, in: Immunomodulators and Nonspecific Host Defence Mechanisms against Microbial Infections (K. N. Masihi and W. Lange, eds.), Pergamon Press, New York, pp. 415–427.Google Scholar
  84. Haak-Frendscho, M., Young, K. M., and Czuprynski, C. J., 1989, Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes, Infect. Immun.57: 3014–3021.PubMedGoogle Scholar
  85. Hadden, J.W., 1992, Recent thoughts on the immunotherapy of infectious diseases including HIV infection, Adv. Exp. Med. Biol.319: 13–22.PubMedGoogle Scholar
  86. Hadden, J. W., Giner-Sorolla, A., and Hadden, E. M., 1991, Methyl inosine monophosphate (MIMP), a new purine immunomodulator for HIV infection, Int. J. Immunopharmacol.13(Suppl. 1): 43–48.Google Scholar
  87. Hagmann, W. K., Ponipipom, N. M., Jackson, J. J., Wood, D. D., Boltz, R. C., and Zweerink, H. J., 1990, Steroidal glycolipid, L-644, 257, is a potent enhancer of nonspecific host resistance, Int. J. Immunopharmacol.12: 241–246.PubMedGoogle Scholar
  88. Hammer, S. M., and Gillis, J. M., 1987, Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro, Antimicrob. Agents Chemother.1987: 1046–1050.Google Scholar
  89. Hammer, S. M., Gillis, J. M., Groopman, J. E., and Rose, R. M., 1986, In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon, Proc. Natl. Acad. Sci. USA 83: 8734–8738.PubMedGoogle Scholar
  90. Handmann, E., and Burgess, A. W., 1979, Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages, J. Immunol.122: 1134–1137.Google Scholar
  91. Havell, E. A., and Sehgal, P. B., 1991, Tumor necrosis factor-independent I1-6 production during murine listeriosis, J. Immunol.146: 756–761.PubMedGoogle Scholar
  92. Hazama, M., Mayumi-Aono, A., Asakawa, N., Kuroda, S., Hinuma, S., and Fujisawa, Y., 1993, Adjuvantindependent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2, Vaccine 11: 629–636.PubMedGoogle Scholar
  93. Heinzel, F. P., Schoenhaut, D. M., Rerko, R. M., Rosser, L. E., and Gately, M. K., 1993, Recombinant interleukin 12 cures mice infected with Leishmania major, J. Exp. Med.177: 1505–1509.PubMedGoogle Scholar
  94. Hersh, E. M., Brewton, G., Abrams, D., Bartlett, J., Galpin, J., Gill, P., Gorter, R., Gottlieb, M., Jonikas, J. J., and Landesman, S., 1991a, Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS, J. Am. Med. Assoc.265: 1538–1544.Google Scholar
  95. Hersh, E. M., Funk, C. Y., Ryschon, K. L., Petersen, E. A., and Mosier, D. E., 1991b, Effective therapy of LP-BM5 murine retrovirus-induced lymphoproliferative immunodeficiency disease with diethyldi- thiocarbamate, AIDS Res. Hum. Retrovir.7: 553–561.PubMedGoogle Scholar
  96. Hockertz, S., Franke, G., Paulini, I., and Lohmann-Matthes, M. L., 1991, Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes, J. Interferon Res.11: 177–185.PubMedGoogle Scholar
  97. Hoffman, S. L., Edelman, R., Bryan, J. P., Schneider, I., Davis, J., Sedegah, M., Gordon, D., Church, P., Gross, M., Silverman, C., Hollingdale, M., Clyde, D., Sztein, M., Losonsky, G., Paparello, S., and Jones, T. R., 1994, Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant, Am. J. Trop. Med. Hyg.51: 603–612.PubMedGoogle Scholar
  98. Hotta, H., Hagiwara, K., Tabata, K., Ito, W., and Homma, M., 1993, Augmentation of protective immune responses against Sendai virus infection by fungal polysaccharide schizophyllan, Int. J. Immunopharmacol.15: 55–60.PubMedGoogle Scholar
  99. Houde, M., and Arora, J. S., 1990, Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase, Cell. Immunol.129: 104–111.PubMedGoogle Scholar
  100. Hubbard, R. D., and Collins, F. M., 1991, Immunomodulation of mouse macrophage killing of Mycobacterium avium in vitro, Infect. Immun.59: 570–574.PubMedGoogle Scholar
  101. Hunter, R. L., Kidd, M. R., Olsen, M. R., Patterson, P. S., and Lai, A. A., 1995, Induction of long-lasting immunity to Plasmodium yoelii malaria with whole blood-stage antigens and copolymer adjuvants, J. Immunol.154: 1762–1769.PubMedGoogle Scholar
  102. Iida, J., Saiki, I., Ishihara, C., and Azuma, I., 1989, Prophylactic activity against Sendai virus infection and macrophage activation with lipophilic derivatives of N-acetylglucosaminylmuramyl tri- or tetrapeptides, Vaccine 7: 225–228.PubMedGoogle Scholar
  103. Iizawa, Y., Nishi, T., Kondo, M., Tsuchiya, K., and Imada, A., 1988, Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice, Infect. Immun.56: 45–50.PubMedGoogle Scholar
  104. Ikeda, S., Matsuura, M., Nakatsuka, M., Homma, J. Y., Kiso, M., Hasegawa, A., and Nishimura, C., 1990, Non-specific protective activity of synthetic lipid A-subunit analogs against microbial infections is influenced by their 2-N- and 3-O-linked acyl substituents in the D-glucosamine backbone, J. Clin. Lab. Immunol.32: 177–181.PubMedGoogle Scholar
  105. Ikeda, S., Neyts, J., Matsuura, M., Kiso, M., Hasegawa, A., Nishimura, C., and De Clerck, E., 1993, Protective activity of the lipid A analogue GLA-60 against murine cytomegalovirus infection in immunodeficient mice, J. Gen. Virol.74: 1399–1403.PubMedGoogle Scholar
  106. Ilbäck, N.-G., Fohlman, J., Slorach, S., and Friman, G., 1989, Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine coxsackievirus B3 myocarditis, J. Immunol.142: 3225–3228.PubMedGoogle Scholar
  107. Irinoda, K., Masihi, K. N., Chihara, G., Kaneko, Y., and Katori, T., 1992, Stimulation of microbicidal host defence mechanisms against aerosol influenza virus infection by lentinan, Int. J. Immunopharmacol.14: 971–977PubMedGoogle Scholar
  108. Ishihara, C., Iida, J., Mizukoshi, N., Yamamoto, N., Yamamoto, K., Kato, K., and Azuma, I., 1989, Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice, Vaccine 7: 309–313.PubMedGoogle Scholar
  109. Ito, M., Baba, M., and Sato, A., 1989, Tumor necrosis factor enhances replication of human immunodeficiency virus in vitro, Biochem. Biophys. Res. Commun.158: 306–312.Google Scholar
  110. Ito, M., Baba, M., Mori, S., Hirabayashi, K., Sato, A., Shigeta, S., and De Clercq, E., 1990, Tumor necrosis factor antagonizes inhibitory effect of azidothymidine on human immunodeficiency virus (HIV) replication in vitro, Biochem. Biophys. Res. Commun.166: 1095–1101.PubMedGoogle Scholar
  111. Izbicki, J. R., Ziegler-Heitbrock, H. W., Luetticken R., Ruckdeschel, G., Wilker, D. K., and Schweiberer, L., 1991, Studies on post-splenectomy infection and immune activation by muramyl peptide. A new concept in the prevention of severe infections, Chirurg 6: 2–8.Google Scholar
  112. Jagodzinski, R R, Wiaderkiewicz, R., Kurazawski, G., Kloczewiak, M., Nakashima, H., Hyjek, E., Yamamoto, N., Uryu, T., Kaneko, Y., Posner, M. R., and Kozbor, D., 1994, Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro, Virology 202: 735–745.PubMedGoogle Scholar
  113. Jeevan, A., and Asherson, G. L., 1988, Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice, Infect. Immun.56: 660–664.PubMedGoogle Scholar
  114. Jensen, W. A., Rose, R. M., Burke, R. H., Anton, K., and Remold, H. G., 1988, Cytokine activation of antibacterial activity in human pulmonary macrophages: Comparison of recombinant interferon gamma and granulocyte-macrophage colony-stimulating factor, Cell. Immunol.117: 369–377.PubMedGoogle Scholar
  115. Johannsen, L., Obal, F., Kapas, L., Kovalzon, V., and Krueger, J. M., 1994, Somnogenic activity of muramyl peptide-derived immune adjuvants, Int. J. Immunopharmacol.16: 109–116.PubMedGoogle Scholar
  116. Johnson, C. S., Chang, M. J., Thurlow, S. M., Pourbohloul, S. C., and Furmanski, P., 1990, Immunotherapeutic approaches to leukemia: The use of Friend virus-induced erythroleukemia model system, Cancer Res.50(Suppl): 5682S-5686S.PubMedGoogle Scholar
  117. Kahn, J. O., Sinangi, F., Baenziger, J., Murcar, N., Wynne, D., Coleman, R. L., Steimer, K. B., Dekker, C. L., and Chernoff, D., 1994, Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers, J. Infect. Dis.170: 1288–1291.PubMedGoogle Scholar
  118. Kalechman, Y., Albeck, M., Oron, M., Sobelman, D., Gurwith, M., Sehgal, S. N., and Sredni, B., 1990, Radioprotective effects of immunomodulator AS101, J. Immunol.145: 1512–1517.PubMedGoogle Scholar
  119. Kalter, C. D., Nakamura, M., Turpin, J. A., Baca, L. M., Hoover, D. L., Dieffenbach, C., Ralph, P., Gendelman, H. E., and Meltzer, M. S., 1991, Enhanced HIV replication in macrophages colony-stimulating factor-treated monocytes, J. Immunol.146: 298–306.PubMedGoogle Scholar
  120. Kaneko, Y., Yamamoto, Y., and Uryu, T., 1990, Biological actions of polysaccharides and those derivatives against cancer and AIDS, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 109–119.Google Scholar
  121. Kaplan, G., 1991, The role of rIL-2 in the modulation of cellular immunity in resistance to infection, Immunol. Lett.30: 199–200.PubMedGoogle Scholar
  122. Karbassi, A., Becker, J. M., Foster, J. S., and Moore, R. N., 1987, Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: Evidence for augmented expression of mannose receptors, Infect. Immun.139: 417–421.Google Scholar
  123. Keitel, W., Couch, R., Bond, N., Adair, S., Van Nest, G., and Dekker, C., 1993, Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant, Vaccine 11: 909–913.PubMedGoogle Scholar
  124. Khaitov, R. M., Pinegin, B. V., Butakov, A. A., and Andronova, T. M., 1994, Immunotherapy of infectious postoperative complications with glucosaminylmuramyl dipeptide, in: Immunotherapy of Infections (K. N. Masihi, ed.), Dekker, New York, pp. 205–211.Google Scholar
  125. Kindler, V., Sappino, A. P., Grau, G. E., Piguet, P. F., and Vassalli, P., 1989, The inducing role of tumor necrosis factor in the development of bacterial granulomas during BCG infection, Cell 56: 731–740.PubMedGoogle Scholar
  126. Klavinski, L. S., Geckeler, R., and Oldstone, M. B., 1989, Cytotoxic T lymphocyte control of acute lymphocytic choriomeningitis virus infection: Interferon gamma, but not tumour necrosis factor alpha, displays antiviral activity in vivo, J. Gen. Virol.70: 3317–3325.Google Scholar
  127. Klempner, M. S., Noring, R., Mier, J. W., and Atkins, M., 1990, An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy, N. Engl. J. Med.322: 959–965.PubMedGoogle Scholar
  128. Kobayashi, N., Hamamoto, Y., Yamamoto, N., Ishii, A., Yonehara, M., and Yonehara, S., 1990, Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication, Proc. Natl. Acad. Sci. USA 87: 9620–9624.PubMedGoogle Scholar
  129. Kohl, S., Loo, L. S., Drath, D. B., and Cox, P., 1989, Interleukin-2 protects neonatal mice from lethal herpes simplex virus infection: A macrophage-mediated, gamma interferon-induced mechanism, J. Infect. Dis.159: 239–247.PubMedGoogle Scholar
  130. Kotani, S., Nagao, A., Tamura, T., Okamura, H., Nagata, K., Aoyama, K., Kusumoto, S., Kokeguchi, S., Kato, K., Fujii, N., Usami, H., Yoshida, T., Akagawa, K., Tanaka, S., Komuro, T., Ikeda-Fujita, T., Kato, Y., and Utsunomiya, J., 1990, Purification and endotoxin-like bioactivities of a novel amphiphile from Mycobacterium bovis BCG, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 19–36.Google Scholar
  131. Kullberg, B.-J., Van’t Wout, J. W., and Van Furth, R., 1990, Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1, Infect. Immun.58: 3319–3324.PubMedGoogle Scholar
  132. Kumaratilake, L. M., Ferrante, A., and Rzepczyk, C., 1991, The role of T lymphocytes in immunity to Plasmodium falciparum. Enhancement of neutrophil-mediated parasite killing by lymphotoxin and IFN-gamma: Comparisons with tumor necrosis factor effects, J. Immunol.146: 762–767.PubMedGoogle Scholar
  133. Lairmore, M. D., Post, A. A., Goldsmith, C. S., and Folks, T. M., 1991, Cytokine enhancement of simian immunodeficiency virus (SIV/mac) from a chronically infected cloned T-cell line (HuT-78), Arch. Virol.121: 43–53.PubMedGoogle Scholar
  134. Lazdins, J. K., Woods-Cook, K., Walker, M., and Alteri, E., 1990, The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages, AIDS Res.10: 1157–1161.Google Scholar
  135. Lee, B. K., Mohrman, M., Odean, M. J., Johnson, A. G., Morin, A., and Deschamps de Paillette, E., 1992, Polyadenylic: polyuridylic acid-induced determinants of host resistance to cytomegalovirus and their potentiation by hyperthermia, J. Immunother.12: 105–114.PubMedGoogle Scholar
  136. Lee, M., and Warren, M. K., 1987, CSF-l-induced resistance to viral infection in murine macrophages, J. Immunol.138: 3019–3022.PubMedGoogle Scholar
  137. Lehn, M., Weiser, W. Y., Engelhorn, S., Gillis, S., and Remold, H. G., 1989, IL-4 inhibits H2O2 production and antileishmanial capacity of human cultured monocytes mediated by IFN-gamma, J. Immunol.143: 3020–3024.PubMedGoogle Scholar
  138. Leiby, D. A., Fortier, A. H., Crawford, R. M., Schreiber, R. D., and Nacy, C. A., 1992, In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies, Infect. Immun.60: 84–89.PubMedGoogle Scholar
  139. Li, H., Jerrells, T. R., Spitalny, G. L., and Walker, D. H., 1987, Gamma interferon as a crucial host defense against Rickettsia conorii in vivo, Infect. Immun.55: 1252–1255.PubMedGoogle Scholar
  140. Liew, F. Y., 1991, Role of cytokines in killing of intracellular pathogens, Immunol. Lett.30: 193–198.PubMedGoogle Scholar
  141. Liew, F. Y. C., Parkinson, S., Millot, A., Severn, A., and Carrier, M., 1990, Tumor necrosis factor (TNF-alpha) in leishmaniasis. I. TNF-alpha mediates host protection against cutaneous leishmaniasis, Immunology 69: 570–573.PubMedGoogle Scholar
  142. Liew, F. Y., Li, Y., Yang, D. M., Severn, A., and Cox, F. E. G., 1991, TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis, Immunology 74: 304–309.PubMedGoogle Scholar
  143. Madonna, G. S., Ledney, G. D., Elliott, T. B., Brook, I., Ulrich, J. T., Myers, K. R., Patchen, M. L., and Walker, R. I., 1989, Trehalose dimycolate enhances resistance to infection in neutropenic animals, Infect. Immun.57: 2495–2501.PubMedGoogle Scholar
  144. Maeda, Y. Y., Yonekawa, H., and Chihara, G., 1994, Application of lentinan as cytokine inducer and host defense potentiator in immunotherapy of infectious diseases, in: Immunotherapy of Infections (K. N. Masihi, ed.), Dekker, New York, pp. 261–279.Google Scholar
  145. Magee, D. M., and Wing, E. J., 1989, Secretion of colony-stimulating factors by T cell clones: Role in adoptive protection against Listeria monocytogenes, J. Immunol.143: 2336–2341.PubMedGoogle Scholar
  146. Maheshwari, R., and Siddiqui, M. U., 1989, Immunoprotection by beta-1, 3 glucan antigen combination in Plasmodium berghei infection in mice, Indian J. Med. Res.89: 396–403.PubMedGoogle Scholar
  147. Makonkawkeyoon, S., Limson-Pobre, R. N., Moreira, A. L., Schauf, V, and Kaplan, G., 1993, Thalidomide inhibits the replication of human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. USA 90: 5974–5978.PubMedGoogle Scholar
  148. Masek, K., Seifert, J., Flegel, M., Krojidlo, M., and Kolinsky, J., 1984, The immunomodulatory property of a novel synthetic compound adamantylamide dipeptide, Meth. Find. Exp. Clin. Pharmacol.6: 667.Google Scholar
  149. Masihi, K. N. (ed.), 1994, Immunotherapy of Infections, Dekker, New York.Google Scholar
  150. Masihi, K. N., and Masek, K., 1993, Effect of the synthetic immunomodulator adamantylamide dipeptide on replication of human immunodeficiency virus alone and in combination with azidothymidine, Int. J. Immunother.IX: 143–150.Google Scholar
  151. Masihi, K. N., and Rohde-Schulz, B., 1990, Application of immunomodulators against infectious diseases, Aerztl. Lab.36: 207–212.Google Scholar
  152. Masihi, K. N., Brehmer, W., Lange, W., Werner, H., and Ribi, E., 1985, Trehalose dimycolate from various mycobacterial species induces differing anti-infectious activities in combination with muramyl dipeptide, Infect. Immun.50: 938–940.PubMedGoogle Scholar
  153. Masihi, K. N., Bhaduri, C. R., Werner, H., Janitschke, K., and Lange, W., 1986a, Effects of muramyl dipeptide and trehalose dimycolate on resistance of mice to Toxoplasma gondii and Acanthamoeba culbertsoni infections, Int. Arch. Allergy Appl. Immunol.81: 112–117.PubMedGoogle Scholar
  154. Masihi, K. N., Lange, W., Brehmer, W., and Ribi, E., 1986b, Immunobiological activities of nontoxic lipid A: Enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects, Int. J. Immunopharmacol.8: 339–345PubMedGoogle Scholar
  155. Masihi, K. N., Lange, W., Rohde-Schulz, B., and Masek, K., 1987, Antiviral activity of immunomodulator adamantylamide dipeptide, Int. J. Immunother.III: 89.Google Scholar
  156. Masihi, K. N., Lange, W., and Özel, M., 1988, Biomedical applications of chromatographic fraction containing trehalose dimycolate in squalane emulsion, J. Chromatogr.440: 473–478.PubMedGoogle Scholar
  157. Masihi, K. N., Kröger, H., Lange, W., and Chedid, L., 1989a, Muramyl peptides confer hepatoprotection against murine viral hepatitis, Int. J. Immunopharmacol.11: 879–886.PubMedGoogle Scholar
  158. Masihi, K. N., Lange, W., and Rohde-Schulz, B., 1989b, Stimulation of antiviral activity by immunomodulators, in: Antiviral Drugs, Basic and Therapeutic Aspects (R. Calio and G. Nistico, eds.), Pythagora Press, Rome, pp. 163–188.Google Scholar
  159. Masihi, K. N., Lange, W., Schwenke, S., Gast, G., Huchshorn, P., Palache, A., and Masek, K., 1990a, Effect of immunomodulator adamantylamide dipeptide on antibody response to influenza subunit vaccines and protection against aerosol influenza infection, Vaccine 8: 159.PubMedGoogle Scholar
  160. Masihi, K. N., Lange, W., Rohde-Schulz, B., and Chedid, L., 1990b, Muramyl dipeptide inhibits replication of human immunodeficiency virus in vitro, AIDS Res. Hum. Retrovir.6: 393–399.PubMedGoogle Scholar
  161. Masihi, K. N., Rohde-Schulz, B., Masek, K., and Palache, B., 1992, Antiviral and adjuvant activity of immunomodulator adamantylamide dipeptide, Adv. Exp. Med. Biol.319: 275–286.PubMedGoogle Scholar
  162. Masood, R., Lunardi-Iskander, Y., Moudgil, T., Zhang, Y., Law, R. E., Huang, C., Puri, R. K., Levine, A. M., and Gill, P. S., 1994, IL-10 inhibits HIV-1 replication and is induced by Tat, Biochem. Biophys. Res. Commun.202: 374–383.PubMedGoogle Scholar
  163. Mastroeni, P., Arena, A., Costa, G. B., Liberto, M. C., Bonina, L., and Hormaeche, C. E., 1991, Serum TNF-alpha in mouse typhoid and enhancement of a salmonella infection by anti-TNF-alpha antibodies, Microb. Pathogen.11: 33–38.Google Scholar
  164. Matsumoto, M., Matsubara, S., Matsuno, T., Tamura, M., Hattori, K., Nomura, H., Ono, M., and Yokota, T., 1987, Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice, Infect. Immun.55: 2715–2720.PubMedGoogle Scholar
  165. Matsuyama, T., Hamamoto, Y., Soma, G., Mizuno, D., Yamamoto, N., and Kobayashi, N., 1989, Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): Enhancement of HIV replication, J. Virol.63: 2504–2509.PubMedGoogle Scholar
  166. Matsuyama, T., Kobayashi, N., and Yamamoto, N., 1991, Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 5: 1405–1417.PubMedGoogle Scholar
  167. Melder, R. J., Balachandran, R., Rinaldo, C. R., Gupta, P., Whiteside, T. L., and Herberman, R. B., 1990, Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells, AIDS Res. Hum. Retrovir.6: 1011–1015.PubMedGoogle Scholar
  168. Melissen, P. M. B., van Vianen, W., Rijsbergen, Y., and Bakker-Woudenberg, I. A. J. M., 1992, Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection, Infect. Immun.60: 95–101.PubMedGoogle Scholar
  169. Melissen, P. M., van Vianen, W., and Bakker-Woudenberg, I. A., 1994, Treatment of Klebsiella pneumoniae septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphatidylethanolamide, Antimicrob. Agents Chemother.38: 147–150.PubMedGoogle Scholar
  170. Mellors, J. W., Griffith, B. P., Ortiz, M. A., Landry, M. L., and Ryan, J. L., 1991, Tumor necrosis factoralpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages, J. Infect. Dis.163: 78–82.PubMedGoogle Scholar
  171. Mestan, J., Digl, W., Mittnacht, S., Hillen, H., Blohm, D., Möller, A., Jacobsen, H., and Kirchner, H., 1986, Antiviral effects of recombinant tumor necrosis factor, Nature 323: 816–819.PubMedGoogle Scholar
  172. Mestan, J. M., Brockhaus, M., Kirchner, H., and Jacobsen, H., 1988, Antiviral activity of tumor necrosis factor. Synergism with interferons and induction of oligo-2′, 5′-adenylate synthetase, J. Gen. Virol.69: 3113–3120.PubMedGoogle Scholar
  173. Michael, M. A., Cottam, H. B., Smee, D. F., Robins, R. K., and Kini, G. D., 1993, Alkylpurines as immunopotentiating agents. Synthesis and antiviral activity of certain alkylguanines, J. Med. Chem.36: 3431–3436.PubMedGoogle Scholar
  174. Moldawer L. L., 1993, Interleukin-1, TNF alpha and their naturally occuring antagonists in sepsis, Blood Purification 11: 128–133.PubMedGoogle Scholar
  175. Moll, H., Binoeder, K., Bogdan, C., Solbach, W., and Röllinghoff, M., 1990, Production of tumor necrosis factor during murine cutaneous leishmaniasis, Parasite Immunol.12: 483–494.PubMedGoogle Scholar
  176. Mooney, D. P., Gameli, R. L., O’Reilly, M., and Herbert, J. C., 1988, Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis, Arch. Surg.123: 1353–1357.PubMedGoogle Scholar
  177. Morrissey, P. J., and Charrier, K., 1990, GM-CSF administration augments the survival of ity-resistant A/J mice, but not ity-susceptible C57BL/6 mice, to a lethal challenge with Salmonella typhimurium, J. Immunol.144: 557–561.PubMedGoogle Scholar
  178. Morrissey, P. J., and Charrier, K., 1991, Interleukin-1 administration to C3H/HeJ mice after but not prior to infection increases resistance to Salmonella typhimurium, Infect. Immun.59: 4729–4731.PubMedGoogle Scholar
  179. Morrissey, P. J., Grabstein, K. H., Reed, S. G., and Conlon, P. J., 1989, Granulocyte/macrophage colony-stimulating factor: A potent activation signal for mature macrophages and monocytes, Int. Arch. Allergy Appl. Immunol.88: 40–45.PubMedGoogle Scholar
  180. Mueller, C., and Zielinski, C. C., 1990, Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis, Hepatology 12: 1118–1124.Google Scholar
  181. Murphy, P. M., Lane, H. C., Gallin, J. I., and Fauci, A. S., 1988, Marked disparity in incidence of bacterial infections in patients with acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma, Ann. Intern. Med.108: 36–41.PubMedGoogle Scholar
  182. Nain, M., Hinder, F., Gong, J. H., Schmidt, A., Bender, A., Sprenger, H., and Gemsa, D., 1990, Tumor necrosis factor production of influenza A virus-infected macrophages and potentiating effect of lipopolysaccharides, J. Immunol.145: 1921–1928.PubMedGoogle Scholar
  183. Nakane, A., Minagawa, T., and Kato, K., 1988a, Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection, Infect. Immun.56: 2563–2569.PubMedGoogle Scholar
  184. Nakane, A., Minagawa, T., Yasuda, I., Yu, C., and Kato, K., 1988b, Prevention by gamma interferon of fatal infection with Listeria monocytogenes infection, Infect. Immun.56: 2011–2015.PubMedGoogle Scholar
  185. Nakano, Y., Onozuka, K., Terada, Y., Shinomiya, H., and Nakano, M., 1990, Protective effect of recombinant tumor necrosis factor-alpha in murine salmonellosis, J. Immunol.144: 1935–1941.PubMedGoogle Scholar
  186. Nathan, C. F., Prendergast, T. J., Wiebe, M. E., Stanley, E. R., Platzer, E and Remold, H. G., 1984, Activation of human macrophages: Comparison of other cytokines with interferon gamma, J. Exp. Med.160: 600–605.PubMedGoogle Scholar
  187. Natuk, R. J., Bukowski, J. F., Brubaker, J. O., and Welsh, R. M., 1989, Antiviral effect of lymphokineactivated killer cells: Chemotaxis and homing to sites of virus infection, J. Virol.63: 4969–4971.PubMedGoogle Scholar
  188. Neifer, S., Kremsner, P. G., and Bienzle, U., 1989, Application of anti-TNF to Plasmodium vinckei-infected mice is followed by an increase of parasitaemia, Acta Trop.46: 273–275.PubMedGoogle Scholar
  189. Nokta, M., Matzke, D., Jennings, M., Schlick, E., Nadler, P., and Pollard, R., 1991, In vivo administration of tumor necrosis factor alpha is associated with antiviral activity in human peripheral mononuclear cells, Proc. Soc. Exp. Biol. Med.197: 144–148.PubMedGoogle Scholar
  190. Nunberg, J. H., Doyle, M. V., York, S. M., and York, C. J., 1989, Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine, Proc. Natl. Acad. Sci. USA 86: 4240–4243.PubMedGoogle Scholar
  191. Obaid, K. A., Ahmad, S., Khan, H. M., Mahdi, A. A., and Khanna, R., 1989, Protective effect of L. donovani antigens using glucan as an adjuvant, Int. J. Immunopharmacol.11: 229–235.PubMedGoogle Scholar
  192. Ozaki, Y., Ohashi, T., Minami, A., and Nakamura, S.-I., 1987, Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-la, Infect. Immun.55: 1436–1440.PubMedGoogle Scholar
  193. Pal, R., Rizvi, S. Y., Kundu, B., Mathur, K. B., and Katiyar, J. C., 1991, Leishmania donovani in hamsters: Stimulation of nonspecific resistance by some novel glycopeptides and impact on therapeutic efficacy, Experientia 47: 486–490.PubMedGoogle Scholar
  194. Parant, M., 1988, Effects of TNF in bacterial infections, Ann. Inst. Pasteur Immunol.139: 301–304.PubMedGoogle Scholar
  195. Parant, M. A., Parant, F. J., Le Contel, C., Lefrancier, P., and Chedid, L., 1992, MDP derivatives and resistance to bacterial infections in mice, Adv. Exp. Med. Biol.319: 175–184.PubMedGoogle Scholar
  196. Pecyk, R. A., Fraser-Smith, E. B., and Matthews, T. R., 1989, Efficacy of interleukin-1β against systemic Candida albicans infections in normal and immunosuppressed mice, Infect. Immun.57: 3257–3258.PubMedGoogle Scholar
  197. Penn, R. L., Nguyen, V. Q., Specian, R. D., Stevens, P., and Berg, R. D., 1991, Interleukin-2 enhances the translocation of Escherichia coli from the intestines to other organs, J. Infect. Dis.164: 1168–1172.PubMedGoogle Scholar
  198. Perno, C. F., Yarchoan, R., Cooney, D. A., Hartman, N. R., Webb, D. S., Hao, Z., Mitsuya, H., Johns, D. G., and Broder, S., 1989, Replication of HIV in monocytes: Granulocyte/macrophage colony-stimulating factor potentiates viral production yet enhances the antiviral effect mediated by AZT and other congeners of thymidine, J. Exp. Med.169: 933–951.PubMedGoogle Scholar
  199. Phillips, N. C., Tsoukas, C., and Chedid, L., 1990, Abrogation of azidothymidine-induced bone marrow toxicity by free and liposomal muramyl dipeptide, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 136–139.Google Scholar
  200. Pohle, C., Rohde-Schulz, B., and Masihi, K. N., 1990, Effects of synthetic HIV peptides, cytokines and monophosphoryl lipid A on chemiluminescence response, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 144–149.Google Scholar
  201. Popova, P., Guencheva, G., Davidkova, G., Bogdanov, A., Pacelli, E., Opalchenova, G., Kutzarova, T., and Koychev, C., 1993, Stimulating effect of DEODAN, an oral preparation from Lactobacillus bulgaricus (“LB51”) on monocytes/macrophages and host resistance to experimental infections, Int. J. Immunopharmacol.15: 25–37.PubMedGoogle Scholar
  202. Porat, R., Clark, B. D., Wolff, S. M., and Dinarello, C. A., 1991, Enhancement of growth of virulent strains of Escherichia coli by interleukin-1, Science 254: 430–431.PubMedGoogle Scholar
  203. Reddehase, M. J., Mutter, W., and Kozinowski, U. H., 1987, In vivo application of recombinant interleukin-2 in the immunotherapy of established cytomegalovirus, J. Exp. Med.165: 650–656.PubMedGoogle Scholar
  204. Reddy, P. G., Blecha, F., Minocha, H. C., Anderson, G. A., Morril, J. L., Fedorka-Cray, P. J., and Baker, P. E., 1989, Bovine recombinant interleukin-2 augments immunity and resistance to bovine herpesvirus infection, Vet. Immunol. Immunopathol.23: 61–74.PubMedGoogle Scholar
  205. Reddy, D. N., Reddy, P. G., Minocha, H. C., Fenwick, B. W., Baker, P. E., Davis, W. C., and Blecha, F., 1990, Adjuvanticity of recombinant bovine interleukin-1 beta: Influence on immunity, infection, and latency in a bovine herpesvirus-1 infection, Lymphokine Res.9: 295–307.PubMedGoogle Scholar
  206. Reed, S. G., Nathan, C. F., Pihl, D. L., Rodricks, P., Shanebeck, K., Conlon, P. J., and Grabstein, K. H., 1987, Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide: Comparison with interferon gamma, J. Exp. Med.166: 1734–1746.PubMedGoogle Scholar
  207. Rezai, H. R., Behbehani, A. B., Gettner, S., and Ardehali, S., 1988, Effect of levamisole on the course of experimental leishmaniasis in guinea-pigs and mice: Haematological and immunological findings, Ann. Trop. Med. Parasitol.82: 243–249.PubMedGoogle Scholar
  208. Richards, R. L., Hayre, M. D., Hockmeyer, W. T., and Alving, C. R., 1988, Liposomes, lipid A, and aluminium hydroxide enhance the immune response to a synthetic malaria sporozoite antigen, Infect. Immun.56: 682–686.PubMedGoogle Scholar
  209. Rickman, L. S., Gordon, D. M., Wistar, R., Krzych, U., Gross, M., Hollingdale, M. R., Egan, J. E., Chulay, J. D., and Hoffman, S. L., 1991, Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine, Lancet 337: 998–1001.PubMedGoogle Scholar
  210. Rieckmann, R, Poli, G., Kehrl, J. H., and Fauci, A. S., 1991, Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, Ul, J. Exp. Med.173: 1–5.PubMedGoogle Scholar
  211. Rifaat, L. K., Mohammad, M. A., and Jawat, S. Z., 1989, Ivermectin, levamisole and thymic extract for chemotherapy and immunostimulation of visceral leishmaniasis in hamsters and mice, Jpn. J. Med. Sci. Biol.42: 51–61.PubMedGoogle Scholar
  212. Roffman, E., and Frenkel, N., 1990, Interleukin-2 inhibits the replication of human herpesvirus-6 in mature thymocytes, Virology 175: 591–594.PubMedGoogle Scholar
  213. Rohde-Schulz, B., Masihi, K. N., and Lange, W., 1990, Reduced replication of human immunodeficiency virus in promonocytic cells by bacterial immunomodulators and anti-retroviral drugs at an early stage of HIV-infection, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 129–133.Google Scholar
  214. Roll, J. T., Young, K. M., Kurtz, R. S., and Czuprynski, C. J., 1990, Human rTNF alpha augments antibacterial resistance in mice: Potentiation of its effects by recombinant human rIL-1 alpha, Immunology 69: 316–322.PubMedGoogle Scholar
  215. Rossol-Voth, R., Rossol, S., Schett, K. H., Corridori, S., de Cian, W., and Falke, D., 1991, In vivo protective effect of tumor necrosis factor alpha against experimental infection with herpes simplex virus type 1, J. Gen. Virol.72: 143–147.PubMedGoogle Scholar
  216. Rouse, B. T., Miller, L. S., Turtinen, L., and Moore, R. N., 1985, Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin-2, J. Immunol.134: 926–930.PubMedGoogle Scholar
  217. Ruggiero, V., Antonelli, G., Gentile, M., Conciatori, G., and Dianzani, F., 1989, Comparative study on the antiviral activity of tumor necrosis factor (TNF)-alpha, lymphotoxin/TNF-beta, and IL-1 in WISH cells, Immunol. Lett.21: 165–170.PubMedGoogle Scholar
  218. Sadick, M. D., Heinzel, F. P., Holaday, B. J., Pu, R. T., Dawkins, R. S., and Locksley, R. M., 1990, Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody, J. Exp. Med.171: 115–127.PubMedGoogle Scholar
  219. Saiki, I., Saito, S., Fujita, C., Ishida, H., Iida, J., Murata, J., Hasegawa, A., and Azuma, I., 1988, Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues, Vaccine 6: 238–244.PubMedGoogle Scholar
  220. Saito, H., Tomioka, H., and Nagashima, K., 1987, Protective and therapeutic efficacy of Lactobacillus casei against experimental murine infections due to Mycobacterium fortuitum complex, J. Gen. Microbiol.133: 2843–2851.PubMedGoogle Scholar
  221. Sakagami, H., Aoki, T., Simpson, A., and Tanuma, S., 1991, Induction of immunopotentiation activity by a protein-bound polysaccharide, PSK [review], Anticancer Res 11: 993–1000.PubMedGoogle Scholar
  222. Sánchez, L., Peña, E., Civantos, A., Sada, G., Alvarez, M. M., Chirigos, M. A., and Villarrubia, V. G., 1995, AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons, J. Hepatol.22: 119PubMedGoogle Scholar
  223. Santoro, M. G., Favalli, C., Mastino, A., Jaffe, B. M., Esteban, M., and Garaci, E., 1988, Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus, Arch. Virol.99: 89–100.PubMedGoogle Scholar
  224. Santoro, M. G., Amici, C., Elia, G., Benedetto, A., and Garaci, E., 1989, Inhibition of virus glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells, J. Gen. Virol.70: 789–800.PubMedGoogle Scholar
  225. Saravolatz, L. D., Wherry, J. C., Spooner, C, Markowitz, N., Allred, R., and Remick, D., 1994, Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha, J. Infect. Dis.169: 214–217.PubMedGoogle Scholar
  226. Sato, Y., Maruyama, S., Kawai, C., and Matsumori, A., 1992, Effect of immunostimulant therapy on acute viral myocarditis in an animal model, Am. Heart J.124: 428–434.PubMedGoogle Scholar
  227. Sazotti, M., Coppenhaver, D. H., Singh, I. P., Poast, J., and Baron, S., 1989, The in vivo antiviral effect of CL246, 738 is mediated by the independent induction of interferon-alpha and interferon-beta, J. Interferon Res.9: 265–274.Google Scholar
  228. Schafer, R., Nacy, C. A., and Eisenstein, T. K., 1988, Induction of activated macrophages in C3H/HeJ mice by avirulent Salmonella, J. Immunol.140: 1638–1644.PubMedGoogle Scholar
  229. Schijns, V. E., Van der Neut, R., Haagmans, B. L., Bar, D. R., Schnellekens, H., and Horzinek, M. C., 1991, Tumour necrosis factor alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells, J. Gen. Virol.72: 809–815.PubMedGoogle Scholar
  230. Schlecht, S., Wiesmueller, K. H., Jung, G., and Bessler, W. G., 1989, Enhancement of protection against Salmonella infection in mice mediated by a synthetic lipopeptide analogue of bacterial lipoprotein in S. typhimurium vaccines, Int. J. Med. Microbiol.1: 271.Google Scholar
  231. Schofield, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R., and Nussenzweig, V., 1987, Gamma interferon, CD8 + T cells and antibodies required for immunity to malaria sporozoites, Nature 330: 664–666.PubMedGoogle Scholar
  232. Schreck, R., Bevec, D., Dukor, R, Baeurle, L., Chedid, L., and Bahr, G.M., 1992, Selection of a muramyl peptide based on its lack of activation of nuclear factor-kB as a potential adjuvant for AIDS vaccines, Clin. Exp. Immunol.90: 188–193.PubMedGoogle Scholar
  233. Scott, R, Pearce, E., Natovitz, P., and Sher, A., 1987, Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes, J. Immunol.139: 221–227.PubMedGoogle Scholar
  234. Sharma, L. K., Jagadish, S., and Mulbagal, A. N., 1990, Effects of haemorrhagic septicaemia vaccination and levamisole administration on the humoral response in cross-bred calves, J. Vet. Pharmacol Ther.13: 23–28.PubMedGoogle Scholar
  235. Sharma, S. D., Hoffin, J. M., and Remington, J. S., 1985, In vivo recombinant interleukin-2 administration enhances survival against a lethal challenge with Toxoplasma gondii, J. Immunol.135: 4160–4163.PubMedGoogle Scholar
  236. Sheron, N., Lau, J. Y., Daniels, H. M., Webster, J., Eddleston, A. L., Alexander, G. J., and Williams, R., 1990, Tumour necrosis factor to treat chronic hepatitis B virus infection, Lancet 336: 321–322.PubMedGoogle Scholar
  237. Shinomiya, N., Tsuru, S., Katsura, Y., Kayashima, S., and Nomoto, K., 1991, Enhanced resistance against Listeria monocytogenes achieved by pretreatment with granulocyte colony-stimulating factor, Infect. Immun.59: 4740–4743.PubMedGoogle Scholar
  238. Sibley, L. D., Adams, L. B., Fukutomi, Y., and Krahenbuhl, J. L., 1991, Tumor necrosis factor-alpha triggers antitoxoplasmal activity of IFN-gamma primed macrophages, J. Immunol.147: 2340–2345.PubMedGoogle Scholar
  239. Siddiqui, W. A., 1990, Role of adjuvants in malaria vaccines, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 325–335.Google Scholar
  240. Sidwell, R. W., Huffman, J. H., Smee, D. F., Gilbert, J., Gessaman, A., Pease, A., Warren, R. P., Huggins, J., and Kende, M., 1992, Potential role of immunomodulators for treatment of phlebovirus infections of animals, Ann. N.Y. Acad. Sci.653: 344–355.PubMedGoogle Scholar
  241. Sidwell, R. W., Morrey, J. D., Okleberry, K. M., Burger, R. A., and Warren, R. P., 1993, Immunomodulator effects on the Friend virus infection in genetically defined mice, Ann. N.Y. Acad. Sci.685: 432–446.PubMedGoogle Scholar
  242. Sidwell, R. W., Smee, D. F., Huffman, J. H., Bailey, K. W., Warren, R. P., Burger, R. A., and Penney, C. L., 1995, Antiviral activity of an immunomodulatory lipophilic desmuramyl dipeptide analog, Antiviral Res.26: 145–159.PubMedGoogle Scholar
  243. Silva, J. S., Twrdzik, D. R., and Reed, S. G., 1991, Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta), J. Exp. Med.174: 539–545.PubMedGoogle Scholar
  244. Smee, D. F., Alaghamandan, H. A., Cottam, H. B., Jolley, W. B., and Robins, R. K., 1990, Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine, J. Biol Response Modif.9: 24–32.Google Scholar
  245. Smee, D. F., Alaghamandan, H. A., Gilbert, J., Burger, R. A., Jin, A., Sharma, B. S., Ramasamy, K., Revankar, G. R., and Cottam, H. B., 1991, Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice, Antimicrob. Agents Chemother.35: 1.Google Scholar
  246. Soike, K. F., Czarniecki, C. W., Baskin, G., Blanchard, J., and Liggitt, D., 1989, Enhancement of simian varicella virus infection in African green monkeys by recombinant human tumor necrosis factor alpha, J. Infect. Dis.159: 331–335.PubMedGoogle Scholar
  247. Sosa, S., Saha, A., Hadden, E. M., and Hadden, J., 1994, Immunological profile of methyl inosine monophosphate, in: Immunotherapy of Infections (K. N. Masihi, ed.), Dekker, New York, pp. 107–113.Google Scholar
  248. Sredni, B., Rosenthal-Galili, Z., Michlin, H., Sobelman, D., Seger, Y., Blagerman, S., Kalechman, Y., and Rager-Zisman, B., 1994, Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101, Immunol. Lett.43: 159–165.PubMedGoogle Scholar
  249. Starnes, H. F., Pearce, M. K., Tewari, A., Yim, J. H., Zou, J. C., and Abrams, J. S., 1990, Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice, J. Immunol.145: 4185–4191.PubMedGoogle Scholar
  250. Stellato, T. A., Townsend, M. C., Gordon, N., Danziger, L. H., Galloway, P., Hawkins, N. L., and Fry, D. E., 1988, Effects of muramyl dipeptide and core body temperature on peritoneal bacterial clearance, Arch. Surg.123: 465–469.PubMedGoogle Scholar
  251. Strube, W., Kretzdorn, D., Grunmach, J., Bergle, R. D., and Thein, P., 1989, The effectiveness of the paramunity inducer Baypamun (PIND-ORF) for the prevention and metaphylaxis of an experimental infection with infectious bovine rhinotracheitis virus in cattle, Tierarztliche Praxis.17: 267–272.PubMedGoogle Scholar
  252. Subauste, C. S., and Remington, J. S., 1991, Role of gamma interferon in Toxoplasma gondii infection, Eur. J. Clin. Microbiol. Infect. Dis.10: 58–67.PubMedGoogle Scholar
  253. Sullivan, R., Fredette, J. P., Leavitt, J. L., Gadenne, A. S., Griffin, J. D., and Simons, E. R., 1989, Effects of recombinant human GM-CSF on transmembrane potentials in granulocytes: Relationship between enhancement of ligand-mediated depolarization and augmentation of superoxide anion production, J. Cell. Physiol.139: 361–369.PubMedGoogle Scholar
  254. Suzuki, K., Lee, W. J., Hashimoto, T., Tanaka, E., Murayama, T., Amitani, R., Yamamoto, K., and Kuze, F., 1994, Recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) or tumor necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex, Clin. Exp. Immunol.98: 169–173.PubMedGoogle Scholar
  255. Suzuki, Y., Joh, K., and Kobayashi, A., 1991, Tumor necrosis factor-independent protective effect of recombinant IFN-gamma against acute toxoplasmosis in T cell-deficient mice, J. Immunol.147: 2728–2733.PubMedGoogle Scholar
  256. Sypek, J. P., Chung, C. L., Mayor, S. H. E., Subramanyam, J. M., Goldman, S. J., Sieburth, D. S., Wolf, S. F., and Schaub, R. G., 1993, Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type immune response, J. Exp. Med.177: 1797–1802.PubMedGoogle Scholar
  257. Takeda, Y., Yoshikai, Y., Ohga, S., and Nomoto, K., 1990, Augmentation of host defense against bacterial infection pretreated intraperitoneally with an alpha-glucan RBS in mice, Immunopharmacol. Immunotoxicol.12: 457–477.PubMedGoogle Scholar
  258. Tamura, M., Yoo, Y. C., Yoshimatsu, K., Yoshida, R., Oka, T., Ohkuma, K., Arikawa, J., and Azuma, I., 1995, Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen, Vaccine 13: 77–82.PubMedGoogle Scholar
  259. Tanaka, M., Hori, Y., Sakai, F., Ueda, H., Goto, T., Okuhara, M., Tsuda, Y., and Okada, Y., 1993, WS1279, a novel lipopeptide isolated from Streptomyces willmorei. Biological activities, J. Antibiot.46: 1699–1706.PubMedGoogle Scholar
  260. Taverne, J., Tavernier, J., Fiers, W., and Playfair, J. H., 1987, Recombinant tumour necrosis factor inhibits malaria parasite in vivo but not in vitro, Clin. Exp. Immunol.67: 1–4.PubMedGoogle Scholar
  261. Ten Hagen, T. L. M., Van Vianen, W., and Bakker-Woudenberg, I. A. J. M., 1995, Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined, J. Infect. Dis.171: 385–392.PubMedGoogle Scholar
  262. Thorel, T., Joseph, M., Capron, A., Vorng, H., and Pascal, M., 1988, In vitro and in vivo immunomodulation by LF1695 of human and rat macrophages and platelets in schistosomiasis, Int. J. Immunopharmacol.10: 739–746.PubMedGoogle Scholar
  263. Titus, R. G., Sherry, B., and Cerami, A., 1989, Tumor necrosis factor plays a protective role in experimental cutaneous leishmaniasis, J. Exp. Med.170: 2097–2105.PubMedGoogle Scholar
  264. Todd, B., Pope, J. H., and Georghiou, P., 1991, Interleukin-2 enhances production in 24 hours of infectious human immunodeficiency virus type 1 in vitro by naturally infected mononuclear cells from seropositive donors, Arch. Virol.121: 227–232.PubMedGoogle Scholar
  265. Tomioka, H., Sato, K., and Saito, H., 1990, Effect of ofloxacin combined with Lactobacillus casei against Mycobacterium fortuitum infection induced in mice, Antimicrob. Agents Chemother.34: 632–636.PubMedGoogle Scholar
  266. Tripp, C. S., Wolf, S. F., and Unanue, E. R., 1993, Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon-gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist, Proc. Natl. Acad. Sci. USA 90: 3725–3729.PubMedGoogle Scholar
  267. Trizio, D., Isetta, A. M., Doria, G. F., Fornasiero, M. C., Ferrari, M., Ferreccio, R., Carminati, P., and Roncucci, R., 1990, Immunopharmacology of a class of synthetics with therapeutic potential in infections and other types of diseases, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 3–8.Google Scholar
  268. Turnek, J., Toman, M., Novak, J., Krchnak, V., and Horavova, P., 1994, Adjuvant effect of liposomes and adamantylamide dipeptide on antigenicity of entrapped synthetic peptide derived from HIV-1 transmembrane region glycoprotein gp41, Immunol. Lett.39: 157–161.Google Scholar
  269. Tursz, T., Morin, A., Deschamps de Paillette, E., and Johnson, A. G., 1990, Poly A-Poly U: An updated review, in: Immunotherapeutic Prospects of Infectious Diseases (K. N. Masihi and W. Lange, eds.), Springer-Verlag, Berlin, pp. 263–272.Google Scholar
  270. Uchiya, K., and Sugihara, H., 1989, Enhancing effect of Salmonella enteritidis SPA on nonspecific resistance, Kansenshogaku Zasshi 63: 463–470.PubMedGoogle Scholar
  271. Uehling, D. T., Hopkins, W. J., and Balish, E., 1990, Decreased immunologic responsiveness following intensified vaginal immunization against urinary tract infection, J. Urol.143: 143–145.PubMedGoogle Scholar
  272. Ungar, B. L., Kao, T. C., Burris, J. A., and Finkelman, F. D., 1991, Cryptosporidium infection in an adult mouse model. Independent roles for IFN-gamma and CD4+ T lymphocytes in protective immunity, J. Immunol.147: 1014–1022.PubMedGoogle Scholar
  273. Urban, J. F., Madden, K. B., Svetic, A., Cheever, A., Trotta, P. P., Gause, W. C., Katona, I. M., and Finkelman, F. D., 1992, The importance of Th2 cytokines in protective immunity to nematodes, Immunol. Rev.127: 205–220.PubMedGoogle Scholar
  274. Van der Meer, J. W. M., Barza, M., Wolff, S. M., and Dinarello, C. A., 1988, A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection, Proc. Natl. Acad. Sci. USA 85: 1620–1623.PubMedGoogle Scholar
  275. Van der Meer, J. W., Helle, M., and Aarden, L., 1989, Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection, Eur. J. Immunol.19: 413–416.PubMedGoogle Scholar
  276. van der Poll, T., Janse, J., van Leenen, D., von der Moehlen, M., Levi, M., and ten Cate, H., 1993, Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia, J. Infect. Dis.168: 955–960.PubMedGoogle Scholar
  277. Vanham, G. L., Kestens, L., van Hoof, J., Penne, G., Colebunders, R., Goilav, C., Vandenbruaene, M., Habib, R. E., and Gigase, P., 1993, Immunological parameters during treatment with ditiocarb (Imuthiol), AIDS 7: 525–530.PubMedGoogle Scholar
  278. Verini, M. A., and Ungheri, D., 1989, Activity of FCE 20696, a new synthetic immunomodulator, in models of viral and bacterial pathology, Immunopharmacology 17: 157–165.PubMedGoogle Scholar
  279. Villarrubia, V. G., Valladolid, J. M., Elorza, F. L., Sada, G., Vilchez, J. G., Jimenez, M., and Herrerias, J. M., 1992, Therapeutic response of chronic active hepatitis B (CAHB) to a new immunomodulator: AM3. Immunohematological effects, Immunopharmacol. Immunotoxicol.14: 141–164.PubMedGoogle Scholar
  280. Vogels, M. T. E., Mensink, E. J. B. M., Ye, K., Boerman, O. C., Verschueren, C. M. M., Dinarello, C. A., and Van der Meer, J. W. M., 1994, Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-l-induced resistance to infection, J. Immunol.153: 5772–5781.PubMedGoogle Scholar
  281. Vyakarnam, A., McKeating, J., Meager, A., and Beverley, P., 1990, Tumor necrosis factors (alpha, beta) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication, AIDS 4: 21–27.PubMedGoogle Scholar
  282. Wang, M., Friedman, H., and Djeu, J. Y, 1989, Enhancement of human monocyte function against Candida albicans by colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-CSF, and macrophage-CSF, Immunol.143: 671–677.Google Scholar
  283. Weinberg, A., and Merigan, T. C., 1988, Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines, J. Immunol.140: 294–299.PubMedGoogle Scholar
  284. Weiser, W. Y., Van Niel, A., Clark, S. C., David, J. R., and Remold, H. G., 1987, Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages, J. Exp. Med.166: 1436–1446.PubMedGoogle Scholar
  285. Williams, D. M., Byrne, G. I., Grubbs, B., Marshal, T. J., and Schachter, J., 1988, Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis, Infect. Immun.56: 3004–3006.PubMedGoogle Scholar
  286. Williams, D. L., Yaeger, R. G., Pretus, H. A., Browder, I. W., McNamee, R. B., and Jones, E. L., 1989, Immunization against Trypanosoma cruzi, adjuvant effect of glucan, Int. J. Immunopharmacol.11: 403–410.PubMedGoogle Scholar
  287. Wong, G. H. W., and Goeddel, D. V., 1986, Tumor necrosis factors α and β inhibit virus replication and synergize with interferons, Nature 323: 819–822.PubMedGoogle Scholar
  288. Wong, G., Krowka, J., and Stites, D. P., 1988, In vitro anti human immunodeficiency virus activities of tumor necrosis factor alpha and interferon gamma, J. Immunol.140: 120–124.PubMedGoogle Scholar
  289. Wyde, P. R., Six, H. R., Ambrose, M. W., and Throop, B. J., 1990, Muramyl dipeptides and polyinosinicpolycytidylic acid given to mice prior to influenza virus challenge reduces pulmonary disease and mortality, J. Biol. Response Modif.9: 98–102.Google Scholar
  290. Yamamoto, N., Fukushima, M., Tsurumi, T., Maeno, K., and Nishiyama, Y., 1987, Mechanism of inhibition of herpes simplex virus replication by prostaglandin A1 and prostaglandin J2, Biochem. Biophys. Res. Commun.146: 1425–1431.PubMedGoogle Scholar
  291. Yoshida, O., Nakashima, H., Yoshida, T., Kaneko, Y., Yamamoto, I., Matsuzaki, K., Uryu, T., and Yamamoto, N., 1989, Sulfation strategy for antivirals to human immunodeficiency virus (HIV), Biochem. Pharmacol.37: 2887–2891.Google Scholar
  292. Yoshida, R., Sato, K., Yoo, Y. C., Yoshimatsu, K., Tamura, M., Ishihara, C., Arikawa, J., and Azuma, I., 1994, Effect of the synthetic lipid A-related compound, DT-5461, on resistance to Sendai virus infection in mice, Immunopharmacology 28: 153–161.PubMedGoogle Scholar
  293. Zhan, Y. F., Stanley, E. R., and Cheers, C., 1991, Prophylaxis or treatment of experimental brucellosis with interleukin-1, Infect. Immun.59: 1790–1794.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • K. Noel Masihi
    • 1
  1. 1.Robert Koch Institute, Federal Institute for Infectious and Non-Communicable DiseasesBerlinGermany

Personalised recommendations